
Acute kidney injury (AKI) involves rapid loss of renal function and occurs in 8–16% of hospitalized patients. AKI can be induced by drugs, sepsis, and ischemia-reperfusion (I/R). Hallmarks of AKI include mitochondrial and microvasculature dysfunction and renal tubular injury. Unfortunately, there is currently no available therapeutic for AKI. In conclusion, lasmiditan treatment beginning with AKI induces MB, attenuated vascular and tubular injury, decreased interstitial fibrosis, and lowered serum creatinine. Given that lasmiditan is a Federal Drug Administration-approved drug, these preclinical data support repurposing lasmiditan as a therapeutic for AKI.
Like
Save
Share